Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
This study examines specific markers (CLL1 and CD45RA) that may help identify leukemia stem cells in acute myeloid leukemia (AML) patients. These markers could potentially help doctors better understand the disease and improve treatment outcomes. The research aims to develop better tools for diagnosing and monitoring AML.
Key Objective: This trial investigates whether measuring leukemia stem cell markers can help identify patients who might benefit from newer AML therapies and improve treatment decisions.
Who to Consider: Patients recently diagnosed with acute myeloid leukemia who are interested in contributing to research that could advance understanding of their disease and help develop better biomarkers for treatment selection should consider enrolling.
Trial Parameters
Brief Summary
Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow and the most common form of acute leukemia in adults. Patient with AML have the shortest survival compared to other forms of leukemia. In the past 6 years, several new therapies have been approved. Biomarkers are in urgent need to guide therapeutic regimen selection in order to maximize the benefit of available therapies and minimize treatment toxicity. Current standard practice is to perform bone marrow biopsy at end of treatment cycle (each cycle around 28 days), and based on bone marrow finding, to decide further treatment plan. It is invasive and time consuming. In this study investigators will study whether tracking leukemia stem cells (LSC) in peripheral blood during early treatment cycle may provide a non-invasive method to predict therapeutic outcome at end of treatment cycle. A retrospective study found that LSC fractional change, defined by two LSC markers, named CLL1 and CD45RA, is highly correlated with therapeutic outcome. Further more, CLL1 and CD45RA positive LSC fraction demonstrates a high concordance between bone marrow and peripheral blood, offering the opportunity to track CLL1 and CD45RA positive LSC fraction non-invasively in peripheral blood during treatment. This pilot study will allow the investigators to decide whether testing CLL1 and CD45RA positive LSC in peripheral blood during leukemia treatment is feasible in clinical practice. This result will lay the foundation for designing future trials using CLL1 and CD45RA positive LSC fractional change to optimize therapeutic strategy for patients with AML.
Eligibility Criteria
Inclusion Criteria: * diagnosis of acute myeloid leukemia * ability to receive treatment for acute myeloid leukemia at the research center * elevated values of CLL1A and CD45RA positive cells at the time of diagnosis